The management of children with Hunter syndrome – a case study
Authors:
- 12 March 2009
- journal article
- case report
- Published by Mark Allen Group in British Journal of Nursing
- Vol. 18 (5) , 321-322
Abstract
Hunter syndrome (mucopolysaccharidosis type II) is a rare lysosomal storage disease caused by a deficiency of the lysosomal enzyme iduronate-2-sulphatase and the subsequent progressive cellular accumulation of glycosaminoglycans. Children with this debilitating disease can now be offered enzyme replacement therapy (ERT) with idursulfase to manage the signs and symptoms of the disease and to improve quality of life. As therapy involves a weekly infusion of enzyme, travel to the few designated specialist centres that provide treatment can be highly disruptive for both patients and carers. Providing ERT outside the hospital setting therefore offers a convenient alternative that can be delivered effectively with specialist nursing support. The authors report their experience of providing ERT to a patient with Hunter syndrome in a school. Through careful planning and the development of close working relationships between nurses, schools, local hospitals and patients’ families, the authors found that managing patients outside the hospital setting can greatly benefit their quality of life.Keywords
This publication has 5 references indexed in Scilit:
- Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type IIActa Paediatrica, 2008
- Recognition and Diagnosis of Mucopolysaccharidosis II (Hunter Syndrome)Pediatrics, 2008
- Idursulfase for the treatment of mucopolysaccharidosis IIExpert Opinion on Pharmacotherapy, 2008
- Home therapy for lysosomal storage disordersBritish Journal of Nursing, 2007
- Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safeJournal of Inherited Metabolic Disease, 2007